根治性前列腺切除术、放疗、化疗和雄激素剥夺疗法是不同形式前列腺癌 (PCa) 最常见的治疗选择。然而，由于在临床实践中缺乏指示治疗结果的可靠预测标记，做出治疗决策很困难。 miRNA 参与 PCa 发育的所有机制，并且易于检测，这使得它们成为有吸引力的 PCa 生物标志物。尽管关于 miRNA 在 PCa 治疗耐药性和敏感性发展中的作用有大量数据，但它们是否可以用作治疗选择的指南，如果可以，我们如何朝着这一目标取得进展，仍不清楚。因此，需要进行概括性的综述和研究，总结、比较和分析 miRNA 参与不同类型 PCa 治疗反应的数据。关于 miRNA 参与治疗反应的数据，关于跨 miRNA 表达在不同治疗中的作用的数据，对 miRNA 靶点进行了分析，以确定 miRNA 相关因素，这可以为 PCa 对治疗的敏感性/耐药性的个性化预测因子的未来发展提供前景。与不同 PCa 疗法（耐药性和敏感性疗法）相关的 miRNA 的可用数据）在本研究中进行了总结和分析，包括使用生物信息学资源的分析。特别关注治疗耐药的发展机制。对当前数据的全面综合分析揭示了一组 miRNA，它们被证明与 PCa 治疗反应最密切相关，并且被发现可以调节与 PCa 相关的基因通过细胞增殖调节、上皮间质转化 (EMT)、细胞凋亡、细胞周期进程、血管生成、转移和侵袭调节、雄激素非依赖性发育和集落形成来进行发育。选定的基于 miRNA 的面板有可能成为指导用于有效治疗 PCa 的治疗决策。© 2023 美国男科学会和欧洲男科学会。

Radical prostatectomy, radiotherapy, chemotherapy, and androgen-deprivation therapy are among the most common treatment options for different forms of prostate cancer (PCa). However, making therapeutic decisions is difficult due to the lack of reliable prediction markers indicating therapy outcomes in clinical practice. The involvement of miRNAs in all mechanisms of the PCa development and their easy detection characterize them as attractive PCa biomarkers. Although there are extensive data on the role of miRNAs in PCa therapy resistance and sensitivity development, the issues of whether they could be used as a guide for therapy choice and, if so, how we can progress toward this goal, remain unclear. Thus, generalizable reviews and studies which summarize, compare, and analyze data on miRNA involvement in responses to different types of PCa therapies are required.Data on the involvement of miRNAs in therapy responses, on the role of cross-miRNA expression in different therapies, and on miRNA targets were analyzed in order to determine the miRNA-related factors which can lend perspective to the future development of personalized predictors of PCa sensitivity/resistance to therapies.The data available on the miRNAs associated with different PCa therapies (resistance and sensitivity therapies) are summarized and analyzed in this study, including analyses using bioinformatics resources. Special attention was dedicated to the mechanisms of the development of therapy resistance.A comprehensive combined analysis of the current data revealed a panel of miRNAs that were shown to be most closely associated with the PCa therapy response and were found to regulate the genes involved in PCa development via cell proliferation regulation, epithelial-mesenchymal transition (EMT), apoptosis, cell-cycle progression, angiogenesis, metastasis and invasion regulation, androgen-independent development, and colony formation.The selected miRNA-based panel has the potential to be a guide for therapeutic decision making in the effective treatment of PCa.© 2023 American Society of Andrology and European Academy of Andrology.